| Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis RL Levine, M Wadleigh, J Cools, BL Ebert, G Wernig, BJP Huntly, ... Cancer cell 7 (4), 387-397, 2005 | 3906 | 2005 |
| A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome J Cools, DJ DeAngelo, J Gotlib, EH Stover, RD Legare, J Cortes, J Kutok, ... New England Journal of Medicine 348 (13), 1201-1214, 2003 | 2175 | 2003 |
| The genetic basis of early T-cell precursor acute lymphoblastic leukaemia J Zhang, L Ding, L Holmfeldt, G Wu, SL Heatley, D Payne-Turner, ... Nature 481 (7380), 157-163, 2012 | 1849 | 2012 |
| Fusion of TEL, the ETS-Variant Gene 6 (ETV6), to the Receptor-Associated Kinase JAK2 as a Result of t(9; 12) in a Lymphoid and t(9; 15; 12) in a Myeloid Leukemia P Peeters, SD Raynaud, J Cools, I Wlodarska, J Grosgeorge, P Philip, ... Blood, The Journal of the American Society of Hematology 90 (7), 2535-2540, 1997 | 614 | 1997 |
| Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants M Debiec-Rychter, J Cools, H Dumez, R Sciot, M Stul, N Mentens, ... Gastroenterology 128 (2), 270-279, 2005 | 591 | 2005 |
| Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1–like phenotype H Brems, M Chmara, M Sahbatou, E Denayer, K Taniguchi, R Kato, ... Nature genetics 39 (9), 1120-1126, 2007 | 534 | 2007 |
| Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia C Graux, J Cools, C Melotte, H Quentmeier, A Ferrando, R Levine, ... Nature genetics 36 (10), 1084-1089, 2004 | 511 | 2004 |
| Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia K De Keersmaecker, ZK Atak, N Li, C Vicente, S Patchett, T Girardi, ... Nature genetics 45 (2), 186-190, 2013 | 456 | 2013 |
| CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy A Pardanani, RP Ketterling, SR Brockman, HC Flynn, SF Paternoster, ... Blood 102 (9), 3093-3096, 2003 | 453 | 2003 |
| Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor … AD Klion, P Noel, C Akin, MA Law, DG Gilliland, J Cools, DD Metcalfe, ... Blood 101 (12), 4660-4666, 2003 | 436 | 2003 |
| The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management J Gotlib, J Cools, JM Malone III, SL Schrier, DG Gilliland, SE Coutré Blood 103 (8), 2879-2891, 2004 | 376 | 2004 |
| The genetics and molecular biology of T-ALL T Girardi, C Vicente, J Cools, K De Keersmaecker Blood, The Journal of the American Society of Hematology 129 (9), 1113-1123, 2017 | 374 | 2017 |
| Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate H Prenen, J Cools, N Mentens, C Folens, R Sciot, P Schöffski, ... Clinical Cancer Research 12 (8), 2622-2627, 2006 | 368 | 2006 |
| Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast C Graux, J Cools, L Michaux, P Vandenberghe, A Hagemeijer Leukemia 20 (9), 1496-1510, 2006 | 358 | 2006 |
| Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification S De Brouwer, K De Preter, C Kumps, P Zabrocki, M Porcu, ... Clinical cancer research 16 (17), 4353-4362, 2010 | 351 | 2010 |
| Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large‐cell lymphoma and inflammatory myofibroblastic tumor J Cools, I Wlodarska, R Somers, N Mentens, F Pedeutour, B Maes, ... Genes, Chromosomes and Cancer 34 (4), 354-362, 2002 | 338 | 2002 |
| Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia I Lahortiga, K De Keersmaecker, P Van Vlierberghe, C Graux, ... Nature genetics 39 (5), 593-595, 2007 | 317 | 2007 |
| PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease J Cools, EH Stover, CL Boulton, J Gotlib, RD Legare, SM Amaral, ... Cancer cell 3 (5), 459-469, 2003 | 271 | 2003 |
| ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia S Peirs, F Matthijssens, S Goossens, I Van de Walle, K Ruggero, ... Blood, The Journal of the American Society of Hematology 124 (25), 3738-3747, 2014 | 252 | 2014 |
| The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia P Van Vlierberghe, M van Grotel, J Tchinda, C Lee, HB Beverloo, ... Blood, The Journal of the American Society of Hematology 111 (9), 4668-4680, 2008 | 252 | 2008 |
